HEALTH TECHNOLOGY

athenahealth Implements DrFirst’s Digital Engagement Solution to Encourage Patients to Follow Prescribed Treatment Plans

athenahealth, Inc. | August 03, 2022 | Read time : 03:00 min

athenahealth Implements

athenahealth, a leading provider of network-enabled software and services for medical groups and healthcare organizations nationwide, and health technology pioneer, DrFirst, today announced they are partnering to help improve medication adherence and patient outcomes. athenahealth’s large user base will now be able to send patient medication notifications powered by DrFirst’s RxInform to reduce prescription abandonment and help patients adhere to their recommended medication therapies.

Patients abandon 20% to 30% of new prescriptions, whether due to high out-of-pocket costs, concerns about side effects, procrastination, or other factors. This lack of medication adherence can lead to increased total cost of patient care and undesirable health outcomes, such as disease progression, hospitalization, or even death.

Now, the athenahealth electronic health record system that helps providers maximize clinical productivity and focus on delivering high-quality care to patients connects with RxInform, which automatically triggers a secure message to a patient’s mobile device when a clinician sends a prescription order to a pharmacy. From the message, patients may receive cost savings opportunities as available for a prescribed therapy and can view detailed information regarding their prescriptions, with a focus on behavioral and educational issues that have been proven to reduce prescription abandonment. The experience is seamless for the prescriber and helps them ensure the best outcomes for their patients.

We are always looking for innovative ways to drive better results for our customers and their patients – especially as the industry shifts more toward value-based care. Every provider wants to minimize prescription abandonment rates because non-adherence to medication regimens negatively affects desired clinical outcomes. By adding RxInform to the latest release of athenaOne, we are immediately giving all our providers an automated function within their established prescribing workflows to support better patient outcomes.”

Paul Brient, chief product officer for athenahealth

Since 2017, RxInform has received more than three million patient ratings, with 92% overall positive scores. These results indicate that patients welcome these messages, presenting new opportunities for providers to nurture patient relationships and build loyalty outside of the exam room.

“Primary care providers and specialists who care for high-risk patients need tools to help people take their medications as prescribed,” said G. Cameron Deemer, president of DrFirst. “We’re pleased to partner with athenahealth to give its network of approximately 145,000 providers access to the RxInform platform so they can help patients overcome the common hurdles that lead them to abandon their medications at the pharmacy.”

About athenahealth, Inc.
athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. 

About DrFirst
Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 290 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada. 

Spotlight

Lactation consultants from St. Elizabeth Hospital provide breastfeeding tips.

Spotlight

Lactation consultants from St. Elizabeth Hospital provide breastfeeding tips.

Related News

HEALTH TECHNOLOGY

Medtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable

Medtronic plc | September 01, 2022

Medtronic plc a global leader in healthcare technology, announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter wearable for continuous, connected monitoring. The partnership enables the Medtronic Patient Monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge. This supports the simplification of care delivery through workflow automation, enabling proactive clinical intervention, and helping to address the implications of staffing shortages. Terms of the deal were not disclosed. The BioButton medical grade device, measuring up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, and heart rate at rest, is the exclusive multi-parameter wearable for the Patient Monitoring business. This device, combined with advanced analytics, has the potential to help enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge. The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings. "Our vision is to empower clinicians and patients with actionable insights to personalize care — anytime, anywhere," said Frank Chan, Ph.D., president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will support continuous, connected care from in-hospital to home and expand our reach to help more patients in more places than ever before." With staffing shortages projected to reach 3.2 million healthcare workers by 20261, the Patient Monitoring business intends to continue to expand its HealthCast™ portfolio to improve workflow automation so clinicians can focus on what matters most — their patients. The HealthCast™ connectivity gateway helps increase workflow efficiency by connecting unconnected devices to the electronic medical records (EMR) and saves valuable staff time by reducing the burden of manual charting. The HealthCast™ VitalSync™ remote patient monitoring system enables clinicians to receive near real-time trend and alert data on web-enabled devices so they can act on patient deterioration earlier. With the addition of the BioButton multi-parameter wearable to the HealthCast portfolio, Medtronic can help even more general care patients inside and outside of the hospital, furthering our commitment to patient safety. "In partnership with Medtronic, we are poised to accelerate continuous connected care models that offer a new level of clinical surveillance and workflow efficiencies for hospitals that are challenged in today's environment of growing workforce shortages and cost of care management. This advanced remote physiologic monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation and proactive clinical interventions." James Mault, M.D., founder and CEO of BioIntelliSense About BioIntelliSense BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring. Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs and physiological biometrics through an effortless patient experience. The medical grade BioButton® devices make remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians have access to high-resolution patient trending and alerting to enable medical grade remote care from in-hospital to home. About the Patient Monitoring business at Medtronic The Patient Monitoring business is committed to transforming the future of health monitoring. Our vision is to empower clinicians and patients with actionable insights to personalize care. Our technologies, including HealthCast™ intelligent patient manager, VitalSync™ remote patient monitoring, Nellcor™ pulse oximetry, Microstream™ capnography, BIS™ brain monitoring, and INVOS™ regional oximetry are always on watch, helping clinicians keep patients safe. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More

HEALTHTECH SECURITY

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More